Table 2. Patients clinical and pathological characteristics in our series.
| Age (years) | Diagnosis | Duration | Surgery | Adjuvant therapy | Size | Gross | Margins | Grade | Local recurrence | Metastases | Last follow-up | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 38 | MXFS | 15 m | R Mast | N | UK | C | N | 2 | 3 y, S | N | DUK, 45 m |
| Case 2 | 38 | F | UK | R Mast | RT | 5 | UK | UK | 2 | N | N | DOC, 5.5 y |
| Case 3 | 31 | PS | 2 m | Excision | N | UK | UK | I | 4 | 1 y, R Mast | N | DOC, 1 y |
| Case 4 | 38 | A | UK | Excision | N | UK | UK | I | 2 | 5 times, 3 to 6 y, S/RT | L, 6 y | DOD, 84 m |
| Case 5 | 72 | PS | UK | R Mast | N | 3 | I | I | 4 | N | N | Alive, 18 y |
| Case 6 | 49 | F | 1 m | Mast | UK | 3 | UK | I | 3 | N | N | DOC, 37 y |
| Case 7 | 43 | A | 1 m | Mast | N | 8 | C | I | 1 | N | B/L, 1 y, S/CT | DOD, 16 m |
| Case 8 | 48 | MXFS | 96 m | Mast | RT | 5.5 | I | I | 3 | 4 m, No TTT | N | AWD, 6 m |
| Case 9 | 55 | F | 2 m | Mast | UK | UK | UK | N | 2 | Twice, 11 m and 17 m, S | N | DOD, 76 m |
| Case 10 | 67 | Le | UK | Excision | CT | 2 | UK | UK | 4 | N | Li/B/Skin, at presentation, CT | DOD, 7 m |
| Case 11 | 39 | A | 2 m | Excision | N | 8 | I | I | 2 | 20 m, S | Li/Jejunum, 9 y, None | DOD, 114 m |
| Case 12 | 32 | PS | 2 m | Excision | N | UK | UK | I | 4 | 2 m, S | N | DOD, 23 m |
| Case 13 | 52 | F | 4 m | M R Mast | N | 4.5 | C | I | 3 | N | N | Alive, NED, 23.5 y |
| Case 14 | 27 | A | 11 m | S Mast | N | 12 | I | I | 2 | 11 m, UK | L/Li/S, 22 m, UK | DOD, 32 m |
| Case 15 | 63 | MXFS | 30 y | S Mast | N | 4 | C | N | 2 | N | N | DOC, 21 y |
| Case 16 | 60 | PS | 12 m | R Mast | RT | 10 | C | N | 4 | N | B/Lu, 6 y, RT | DOD, 88 m |
| Case 17 | 55 | Le | UK | Mast | N | 4 | UK | N | 4 | N | Multiple sites, 6 y, CT | DOD, 77 m |
| Case 18 | 33 | A | 12 m | R Mast | RT | 10 | C | I | 2 | 10 m, UK | B, 10 m, RT | DOD, 13 m |
| Case 19 | 33 | HPC | UK | UK | UK | UK | UK | N | 4 | N | L/Li/Pelvis, UK, RT | DOD, 41 m |
| Case 20 | 24 | PS | 12 | S Mast | N | 5 | C | I | 3 | N | N | Alive, NED, 11 y |
| Case 21 | 32 | A | 11 m | S Mast | N | UK | UK | I | 3 | 14 m, RT | B/L, 14 m, RT/CT | DOD, 26 m |
| Case 22 | 42 | F | UK | S Mast | N | 3 | UK | I | 3 | 8 m, S | N | DOC, 49 y |
| Case 23 | 54 | F | 1 m | M R Mast | N | 5 | UK | N | 2 | N | N | Alive, NED, 13 y |
| Case 24 | 81 | PS | UK | M R Mast | N | 0.3 | UK | I | 4 | N | N | Alive, NED, 14 m |
| Case 25 | 54 | OGS | UK | M R Mast | N | 10 | C | I | 3 | N | N | Alive, NED, 4 y |
Abbreviations: MXFS = myxofibrosarcoma; F = fibrosarcoma; PS = pleomorphic sarcoma; AGS = angiosarcoma; Le = leiomyosarcoma; HPC = hemangiopericytoma; OGS = osteosarcoma; UK = unknown; R = radical; Mast = mastectomy; S = simple; M = modified; RT = radiotherapy; CT = chemotherapy; C = circumscribed; I = infiltrative; y = year; m = month; DOC = dead of other causes; DUK = dead of unknown cause; NED = no evidence of disease; DOD = dead of disease; Lu = lung; B = bone; Li = liver; S = spleen; N = nodular or pushing margins; I = infiltrative.